

SCOTT C. N. OLIVER, M.D.
Rocky Mountain Lions Eye Institute
University of Colorado Denver
1675 Aurora Court
P.O. Box 6510, Mail Stop F-731
Aurora, CO 80045

FACULTY APPOINTMENTS

- 2008- Assistant Professor, Department of Ophthalmology, Rocky Mountain Lions Eye Institute, University of Colorado Denver
- 2008- Associate Member, Developmental Therapeutics Program, University of Colorado Cancer Center, Department of Medicine, Division of Oncology, University of Colorado Denver
- 2006-2008 Clinical Instructor, Retina Division, Department of Ophthalmology, Jules Stein Eye Institute, UCLA

DEPARTMENTAL APPOINTMENTS

- 2008- Director, Ophthalmic Oncology Center, Rocky Mountain Lions Eye Institute, University of Colorado Denver
- 2008- Director, Ocular Imaging Center, Rocky Mountain Lions Eye Institute, University of Colorado Denver

BOARD CERTIFICATION

- 2008 Diplomate, American Board of Ophthalmology

EDUCATION & TRAINING

- 2006-2008 Fellowship in Vitreoretinal Diseases and Surgery, Jules Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
- 2006-2008 Fellowship in Ophthalmic Oncology, Jules Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
- 2003-2006 Residency in Ophthalmology, Rocky Mountain Lions Eye Institute, University of Colorado, Aurora, Colorado,
- 2002-2003 Internship in Internal Medicine, Saint Joseph Hospital, Exempla Healthcare, Denver, Colorado.
- 1998-2002 Doctor of Medicine, University of Colorado Health Sciences Center, Denver, Colorado.
- 1994-1998 Bachelor of Arts, *Magna cum Laude*, Trinity University, San Antonio, Texas.

HONORS & AWARDS

- 2009 ARVO Travel Grant Award
- 2008 Fellow's Teaching Award, Jules Stein Eye Institute, UCLA
- 2007-2008 Frederic G. Rappaport Fellow in Retinal Diseases & Ocular Oncology, Jules Stein Eye Institute, UCLA
- 2007-2008 Rosalind Alcott Fellow, Jules Stein Eye Institute, UCLA
- 2006-2007 Abe Meyer Memorial Fellow, Jules Stein Eye Institute, UCLA
- 2005-2006 Administrative Chief Resident, Department of Ophthalmology, University of Colorado Denver
- 2003 Intern of the Year, St. Joseph Hospital, Denver, CO
- 2002 *Alpha Omega Alpha*, University of Colorado
- 1999 Merck Award for Excellence in Medical Education, University of Colorado
- 1998 *Phi Beta Kappa*, Trinity University
- 1996 Sophomore Chemistry Achievement Award, Merch & Company, Trinity University
- 1995 Freshman Chemistry Achievement Award, Chemical Rubber Company, Trinity University
- 1994-1998 Murchison Academic Scholarship, Trinity University
- 1994 International Baccalaureate Diploma, Colorado Springs, CO
- 1994 Eagle Scout

PATENT

U.S. Provisional Application Serial No. 61/143,310, filed 01/08/2009. **Scott CN Oliver**, Tara A Young, Min Y Leu.

PEER REVIEWED PUBLICATIONS

1. Dixon JA, **Oliver SCN**, Olson JL, Mandava N. Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration. *Expert Opin. Investig. Drugs* (2009) 18(10):1-8.
2. Hu AYH, Bourges JL, Shah SP, Gupta A, Gonzales CR, **Oliver SCN**, Schwartz SD. Endophthalmitis after Pars Plana Vitrectomy: a 20- and 25-gauge comparison. *Ophthalmology* 2009;116:1360–1365
3. Wen JC, **Oliver SCN**, McCannel TA. Ocular Complications Following I-125 Brachytherapy for Choroidal Melanoma. *Eye*, 2009 Jun;23(6):1254-68. Epub 2009 Mar 6.
4. **Oliver SCN**, Young TA, Kobe LH, Leu MY, Chun MW, Straatsma BR. Surveillance of central vision and macular structure in patients undergoing Iodine-125 plaque brachytherapy for ciliochoroidal melanoma. *Am J Clin Oncology*, 2008.
5. Hink E, **Oliver SCN**, Drack AV, Hawes M, Wojno TH, Durairaj VD. Pediatric golf-related ophthalmic injuries. *Arch Ophthalmol.* 2008;126(9):1252-1256.
6. Kelmenson AT, **Oliver SCN**, Durairaj VD. Sarcoid-Induced Symblepharon. *Indian J Ophthalmol.* 2008 Jul-Aug; 56(4):344.
7. **Oliver SCN**, Mandava N. Optic nerve and retinal avulsion: ultrasonographic signs. *Arch Ophthalmol.* 2007 May; 125(5):716.
8. **Oliver SCN**, Ciardella AP, Sands RE, Conway J, Yannuzzi L, Durairaj VD. Posterior scleral choristomas and trigeminal lipoma in the organoid nevus syndrome. *Retinal Cases & Brief Reports.* 2007 Spring; 1(2):82-84.
9. **Oliver SCN**, Bennett JB. Genetic disorders and the optic nerve: a clinical survey. *Ophthalmol Clin N Am.* 2004 Sep; 17(3): 435-445.
10. Murphy DJ, Gahm GJ, Santilli S, North P, **Oliver SCN**, Shapiro H. Seniors' preferences for cancer screening and medication use based on absolute risk reduction. *J Gerontol Biol Sci Med Sci.* 2002 Feb; 57(2):M100-M105.

PUBLICATIONS IN PRESS

1. Kaines A, **Oliver SCN**, Schwartz SD. Ultrawide Angle Angiography for the Detection and Management of Diabetic Retinopathy. In press, *Int Ophthalmol Clin.*
2. Prasad PS, **Oliver SCN**, Gonzales CR. Midlenticular optic opacification of a hydrophobic acrylic intraocular lens in association with retained perfluorocarbon liquid following vitreoretinal surgery. In press, *Ophth Surg Lasers Imaging.*

PUBLICATIONS UNDER REVIEW

1. **Oliver SCN**, Leu MY, DeMarco JJ, Chow PE, Lee SP, McCannel, TA. Attenuation of Iodine-125 Radiation with _____ in the Treatment of Uveal Melanoma. Submitted to *Arch Ophthalmol.*
2. Olson JL, Quiroz-Mercado HQ, **Oliver SCN**, Mandava N. Novel Protein Inhibitor of Cell Migration Decreases Experimental Choroidal Neovascularization in an Animal Model. Submitted to *Invest Ophth Vis Sci.*
3. Kunjukunju N, Quiroz-Mercado H, Mandava N, Navarro A, Oliver SCN, Olson JL, Patel C. Bilateral Macular Hole Formation secondary to Sclopteria. Submitted to *BMC Ophthalmology.*
4. DeMarco JJ, Leu MY, Kobe LH, Chow P, **Oliver SCN**, Young TA. A Monte Carlo simulation model for eye plaque dosimetry. Submitted to *Medical Physics.*
5. Pan CK, **Oliver SCN**. Periorbital (Preseptal) Cellulitis. Submitted to Bajaj, L, ed. *Berman's Pediatric Decision Making, 5th Edition.*
6. Pan CK, **Oliver SCN**. Orbital Cellulitis or Abscess. Submitted to Bajaj, L, ed. *Berman's Pediatric Decision Making, 5th Edition.*
7. Pan CK, **Oliver SCN**. Ocular Injury. Submitted to Bajaj, L, ed. *Berman's Pediatric Decision Making, 5th Edition.*
8. Pan CK, **Oliver SCN**. Evaluation of Poor Vision. Submitted to Bajaj, L, ed. *Berman's Pediatric Decision Making, 5th Edition.*

9. Seibold LK, **Oliver SCN**. Evaluation Strabismus (Eye Misalignment). Submitted to Bajaj, L, ed. *Berman's Pediatric Decision Making, 5th Edition*.
10. Seibold LK, **Oliver SCN**. Conjunctivitis/Red, Painful Eye. Submitted to Bajaj, L, ed. *Berman's Pediatric Decision Making, 5th Edition*.
11. **Oliver SCN**, Schwartz SD. Peripheral Non-Perfusion and Late Leakage from Peripheral Vessels (LLPV): Association between Peripheral Abnormalities and Active Diabetic Retinopathy Detected Using Ultra Wide-Field Fluorescein Angiography. Submitted to *Ophthalmology*.
12. Fante RJ, Durairaj VD, **Oliver SCN**. Diabetic Retinopathy: An Update on Treatment. Submitted to *American Journal of Medicine*.

INVITED CHAPTERS

1. Tenku KE, Kahook MY, Barnett C, Mandava N, **Oliver SCN**. Imaging for Diabetic Macular Edema: An Overview of the Retina Module of the Heidelberg Retina Tomograph 3. *Retina Today*, May/June 2009.
2. **Oliver SCN**, Schwartz SD. Ultra-wide angle fluorescein angiography, in Arevalo F, ed. *Retinal Imaging Techniques*. New York: Springer Publishing Co., 2008.
3. **Oliver SCN**. Current Diagnostic, Preventive, and Investigational Therapies for Age-Related Macular Degeneration, in Flynn HW, ed. *The Ophth Report*. 2008 Winter; 1(2):12-18.
4. **Oliver SCN**, Ciardella AP, Ferrara DCAC, Slakter JS, Yannuzzi LA. Indocyanine Green Angiography in Age-Related Macular Degeneration, in Lim JI, ed. *Age-Related Macular Degeneration, 2nd ed*. New York: Taylor & Francis, 2007.

PUBLICATIONS (Trade & Press Coverage)

1. Oliver, SC. Reaching for the Periphery: Learn how you can use ultra wide-field imaging to improve patient care. *Retinal Physician*, March 2009.
2. Insider Medicine. Ophthalmic Injuries Among Children Is Generally Preventable. Physician Version:
http://www.insidermedicine.com/archives/Ophthalmic_Injuries_Among_Children_Playing_Golf_Generally_Preventable_2849.aspx. Accessed Nov 11, 2008
3. Insider Medicine. Ophthalmic Injuries Among Children Is Preventable. Patient Version:
http://www.insidermedicine.com/archives/Golf_Related_Eye_Injuries_Among_Children_Preventable_2848.aspx. Accessed Nov 11, 2008.
4. Oliver, SC. The KOL Corner: Posterior Segment Trauma. *Retina Times*, 2008 Summer; 25:33-35.

GRANTS

1. American Cancer Society Institutional Research Grant #57-001-50. Attenuation of Iodine-125 Radiation with [confidential] in an Animal Model for the Treatment of Ocular Melanoma. \$30,000.
2. University of Colorado Cancer Center, Student Cancer Summer Research Fellowship. \$1,300 for support of medical student researcher.

CURRENT INVESTIGATOR INITIATED RESEARCH

1. Ramamoorthy P, **Oliver SCN**, Olson JL, Quiroz-Mercado H, Mandava, N. Analysis of DNA biomarkers involved in age-related macular degeneration (AMD).
2. **Oliver SCN**, Leu MY, DeMarco JJ, Young TA Monte Carlo radiation dosimetry modeling for multi-seed Iodine-125 gold plaque brachytherapy for ocular melanoma.
3. **Oliver SCN**, Leu MY, DeMarco JJ, Young TA. Radiation reduction during plaque radiotherapy for ocular melanoma.
4. **Oliver SCN**, Quiroz-Mercado H, Olson JL, Mandava N. Intrector for endophthalmitis.

PRESENTATIONS & ABSTRACTS

1. Hsu V, **Oliver SCN**. Attenuation of Iodine-125 Radiation with _____ in an Animal Model for the Treatment of Ocular Melanoma. University of Colorado Cancer Center Student Cancer Research Fellowship Program, Poster Presentation, Aurora, CO. August 6, 2009.

2. **Oliver SCN**. Advances in Age-Related Macular Degeneration (AMD). Glaucoma Education, Resources, and Support Group (GERS) of Denver, invited lecture. July 11, 2009. Aurora, CO
3. **Oliver SCN**, Hu AY, Bourges JL, Shah SP, Gupta A, Gonzales CR, Schwartz SD. Endophthalmitis after Pars Plana Vitrectomy: A 20- and 25-Gauge Comparison. Rocky Mountain Lions Eye Institute 13TH Annual Ophthalmology Resident, Fellow & Faculty Research Day, Paper Presentation, June 13, 2009.
4. Courtney RJ, Mandava N, **Oliver SCN**, Quiroz-Mercado H, Olson JL. Intravitreal Inhibition of CNV in an Animal Model: A Comparison of Infliximab, Anakinra and LD22-4. Association for Research in Vision and Ophthalmology, Poster #2964/A418, May 5, 2009
5. Pan CK, Mandava N, **Oliver SCN**, Quiroz-Mercado H, Olson JL. Comparison of Concentration and Dosage of Intravitreal Recombinant IL-1 Receptor Antagonist in the Treatment of Choroidal Neovascular Membranes in a Rat Model. Association for Research in Vision and Ophthalmology, Poster #2971/A425, May 5, 2009.
6. Hendrick AM, Mandava N, Quiroz-Mercado H, **Oliver SCN**, Pelak V, Olson JL. Bevicizumab for Parry-Romberg Syndrome (PRS) Associated Optic Nerve Edema: An Optical Coherence Tomography (OCT) Case Report. Association for Research in Vision and Ophthalmology, Poster #3261/A279, May 5, 2009.
7. **Oliver SCN**, Coffee RE, Schwartz SD. Peripheral Vessel Leakage and Capillary Non-Perfusion - The Ischemic Index in Central Retinal Vein Occlusion? Association for Research in Vision and Ophthalmology, Poster #3261/A279, May 5, 2009.
8. Korotkin A, Quiroz-Mercado H, Mandava N, Olson JL, **Oliver SCN**, Garcia G, Grinblat A. Vitreo-Retinal Dissector (VRD) for Pars Plana Vitrectomy. Association for Research in Vision and Ophthalmology, Poster #4459/A596, May 6, 2009.
9. Hu AY, Bourges JL, Shah SP, Gupta A, Gonzales CR, **Oliver SCN**, Schwartz SD. Endophthalmitis after Pars Plana Vitrectomy: A 20- and 25-Gauge Comparison. Association for Research in Vision and Ophthalmology, Paper #5203, May 7, 2009.
10. Coffee RE, **Oliver SCN**, Schwartz SD, Friberg TR. The Development of an Ischemic Index for Assessing Diabetic Macular Edema with Scanning Laser Ophthalmoscopic Ultra Wide Field Angiographic Imaging. Association for Research in Vision and Ophthalmology, Poster #5271/A132, May 7, 2009.
11. Tsui I, McCannel TA, **Oliver SCN**, Chun MW, Kobe LH, Leu MY, Lee SP, Yu F, Nulliah T, Straatsma BR. Central Vision After Treatment of Ciliochoroidal Melanoma With Iodine-125 Brachytherapy. Association for Research in Vision and Ophthalmology, Paper # 5705, May 7, 2009.
12. **Oliver SCN**. Diabetic Retinopathy for the Non-Ophthalmologist. Invited Grand Rounds Lecture, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver. March 18, 2009.
13. **Oliver SCN**, Schwartz SD. Peripheral Non-Perfusion and Late Peripheral Vessel Leakage – The Angiographic Index for Active Diabetic Retinopathy? 26th Annual American Society of Retina Specialists Annual Meeting Maui, HI. Paper Presentation, October 13, 2008.
14. **Oliver SCN**, Schwartz SD. Peripheral Non-Perfusion and Late Peripheral Vessel Leakage – The Angiographic Index for Central Retinal Vein Occlusion? 26th Annual American Society of Retina Specialists Annual Meeting Maui, HI. Poster Presentation, October 14, 2008.
15. Hu AYH, Bourges JL, Shah SP, Gupta A, Gonzales CR, **Oliver SCN**, Schwartz SD. Endophthalmitis after Pars Plana Vitrectomy: a 20- and 25-gauge comparison. 26th Annual American Society of Retina Specialists Annual Meeting Maui, HI. Paper Presentation, October 14, 2008.
16. Prasad PS, **Oliver SCN**, Schwartz SD. Wide Angle Angiographic Characteristics of Branch Retinal Vein Occlusion and Hemicentral Retinal Vein Occlusion. 26th Annual American Society of Retina Specialists Annual Meeting Maui, HI. Paper Presentation, October 14, 2008.
17. **Oliver SCN**. Advances in Angiography for Retinal Vascular Disease. The 12th Annual Ophthalmology Symposium, University of Colorado Denver, September 19, 2008.
18. **Oliver SCN**, Schwartz SD. The Ischemic Index? Peripheral Non-Perfusion and Late Peripheral Vessel Leakage in Diabetic Retinopathy. The Jules Stein Eye Institute Annual Research Day Paper Presentation, May 30, 2008.

19. Prasad PS, **Oliver SCN**, Schwartz SD. Ultra wide-field angiographic characteristics of branch retinal vein and hemicentral retinal vein occlusion. The Jules Stein Eye Institute Annual Research Day Paper Presentation, May 30, 2008.
20. Hu AYH, Bourges JL, Shah SP, Gupta A, Gonzales CR, **Oliver SCN**, Schwartz SD. Endophthalmitis after Pars Plana Vitrectomy: a 20- and 25-Gauge Comparison. The Jules Stein Eye Institute Annual Research Day Paper Presentation, May 30, 2008.
21. Schwartz SD, **Oliver SCN**, Gonzales CR. Association of Peripheral Retinal Vascular Abnormalities Detected on Ultra Wide-Field Fluorescein Angiography With Diabetic Macular Edema and Neovascularization. Association for Research in Vision and Ophthalmology, Paper #4524, April 30, 2008.
22. **Oliver SCN**. Ultra Wide-Field Fluorescein Angiography. Jules Stein Eye Institute, University of California, Los Angeles. Invited Ophthalmology Grand Rounds lecture, February 27, 2008.
23. **Oliver SCN**. Ultra Wide-Field Fluorescein Angiography. Casey Eye Institute, Oregon Health Sciences University, Portland, OR. Invited fluorescein angiography conference lecture, January 11, 2008.
24. **Oliver SCN**, Gonzales CR, Gupta A, Kreiger AE, Young TA, Schwartz SD. Ultra-widefield fluorescein angiography for detection of peripheral retinal pathology. 25th Annual Meeting of the American Society of Retina Specialists, Indian Wells, CA. Paper Presentation, December 4, 2007.
25. **Oliver SCN**, Gonzales CR, Gupta A, Schwartz SD. Zero cases of endophthalmitis in 1000+ consecutive 25-gauge transconjunctival sutureless vitrectomies: the benefit of vitreous wick repositioning. 25th Annual Meeting of the American Society of Retina Specialists, Indian Wells, CA. Poster Presentation, December 1-5, 2007.
26. **Oliver SCN**. Ultra Wide-Field Fluorescein Angiography. Rocky Mountain Lions Eye Institute, University of Colorado, Aurora, CO. Invited Grand Rounds Lecture, November 16, 2007.
27. **Oliver SCN**, Young TA, Burgess B, Chun MW, Moral JN, Straatsma BR. Prospective Surveillance of Visual Function in Patients with Ocular Melanoma Undergoing Iodine-125 Plaque Brachytherapy. Association for Research in Vision and Ophthalmology, Poster #5262, May 10, 2007.
28. **Oliver SCN**. Indocyanine Green Angiography in Age-Related Macular Degeneration, Rocky Mountain Lions Eye Institute Seminar, 2006.
29. **Oliver SCN**. Age-related macular degeneration: what's new and what's in the pipeline. Rocky Mountain Lions Eye Institute Resident Seminar, June 2005.
30. **Oliver SCN**, Petty S. A Retrospective Study of Transpupillary Thermotherapy (TTT) for Choroidal Neovascularization in AMD. Association for Research in Vision and Ophthalmology, Poster #1405, May 2005.
31. **Oliver SCN**, Ciardella AP, Durairaj VD, Sands RE, Conway J. Early Diagnosis of Organoid Nevus Syndrome, a Rare Phakomatosis: Implications for Surgical Management. Association for Research in Vision and Ophthalmology, Poster #3570, April 2004.
32. **Oliver SCN**. Emerging Treatments for Retinal Vein Occlusion. Rocky Mountain Lions Eye Institute Resident Seminar, April 2004
33. **Oliver SCN**, Murphy JD. Long Term Stability of Seniors' Preferences for Life-Sustaining Interventions. Western Student Medical Research Forum, Carmel, CA, February, 2000.
34. **Oliver SCN**, Murphy JD. Developing Community Consensus for Life Sustaining Interventions. The UNMHSC Biomedical Ethics Committee 7th Annual Symposium, Albuquerque, NM, October, 1999.
35. **Oliver SCN**. Load Testing of Geodesic Domes. The 10th Annual Junior Sciences and Humanities Symposium, 1992. Knoxville, TN.

LECTURES AND INSTRUCTIONAL COURSES

Ophthalmic Knowledge Assessment Program – Resident Review, Retina Section

Basic and Clinical Science Course – Retina and Uveitis Review Lectures

Vitreoretinal Surgery Orientation Lecture – Ronald Reagan Medical Center, Los Angeles, CA

CLINICAL TRIALS INVESTIGATOR

Principal Investigator

1. Genentech FVF3426g (HORIZON): An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Or Macular Edema Secondary To Retinal Vein Occlusion (RVO) Who Have Completed the Treatment Phase of a Genentech Sponsored Ranibizumab Study. Project # 2585036, \$19,461.
2. Thrombogenics, Inc., TG-MV-006: The MIVI-TRUST [Traction Release withOut Surgical Treatment] Trial: A randomized, sham-injection controlled, double-masked, multicenter trial of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular adhesion. Award #PN090249, \$94,534.00.

Subinvestigator

1. Alcon AART, #C-02-60: An evaluation of efficacy and safety of posterior juxtасcleral administrations of anecortave acetate for depot suspension (15 or 30 mg) versus sham administration in patients (enrolled in study "A" or study "B") at risk for developing sight-threatening choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).
2. Allergan Posurdex DME Study, # 206207-008: A 3-year, phase 3, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS Applicator System) in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion.
3. Allergan Posurdex RVO Study, # 206207-011: A 3-year, phase 3, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS Applicator System) in the treatment of patients with diabetic macular edema.
4. BLOCK-ROP: Pan-VEGF BLOCKade for the Treatment of ROP Study: Study of the Safety of a Single Intravitreal Injection of Avastin in One Eye for the Treatment of the Aggressive Posterior Form of Retinopathy of Prematurity (ROP) in Both Eyes After No Favorable Response from Laser Treatment.
5. Eyetech, # EOP1013: A phase IV, open label, multi-center trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement
6. Genentech 07-0461: A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion
7. Genentech 07-0462: A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion
8. Genentech 07-0687: A randomized, double masked, active controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degeneration.
9. Genentech 07-0782: A phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus.
10. Genentech Lucentis for CSME, #FVF4168g: A phase III, double-masked, multi-center, randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes.
11. A Natural History Study of Parafoveal Telangiectasia - the MacTel Study
12. NEI/NIH AREDS2 (Age-Related Eye Disease Study): A multi-center, randomized trial of lutein, zeaxanthin, and omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA] in age-related macular degeneration.

13. Ophthotech: A Phase 1, Single Ascending Dose Trial to Establish the Safety, Tolerability, and Pharmacokinetic Profile of Intravitreal Injections of E10030 (Anti-PDGF Pegylated Aptamer) Monotherapy and of E10030 Given in Combination with Lucentis® 0.5mg/eye in Subjects with Neovascular Age-Related Macular Degeneration
14. Pfizer Early AMD Lesions Study; A prospective, open-label, multi-center trial evaluating the safety and efficacy of 0.3mg/eye intravitreal injection of pegaptanib sodium (Macugen®) given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration with evidence of recent onset choroidal neovascularization.
15. Pfizer Macugen for BRVO Study: Open Label Macugen for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO).
16. Sirion Therapeutics, # SRFR-001: A phase II multicenter, randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in subjects with age-related macular degeneration.
17. Thrombogenics, Inc., The MIVI III [Microplasmin for Vitreal Injection III] Trial: A multicenter, randomized, placebo-controlled, double-masked, dose-ranging trial of intravitreal microplasmin in patients undergoing surgical vitrectomy
18. University of Colorado 07-0446: Ocular Ranibizumab for Ischemic Optic Neuropathy (ORION). Investigator Sponsored Trial supported by Genentech

INSTITUTIONAL SERVICE

- 2008- Director, Rocky Mountain Lions Eye Institute Tumor Board
- 2008- Retina Surgical Service OR Liason
- 2009 Doctors' Line 9, Nine News Community Volunteer
- 2008- Director, Morning Report Teaching Conference
- 2008- Faculty Senator, Department of Ophthalmology, UC Denver
- 2008-2009 Basic & Clinical Science Course Committee, Section Coordinator, Retina and Uveitis
- 2008- Retina Fellowship Selection Committee, UC Denver
- 2005, 2008- Resident Selection Committee, Rocky Mountain Lions Eye Institute, UC Denver
- 2005 Basic & Clinical Science Course Committee, Section Coordinator, Update on General Medicine, UCHSC
- 2004-2005 Colorado Society of Eye Physicians and Surgeons, Resident Representative
- 2003-2006 Editor, Resident Grand Rounds & Morning Report Compilation on CD-ROM, UCHSC
- 1998-2002 UCHSC Curriculum Committee
- 1998-1999 UCHSC Working Group on Course Evaluations

PROFESSIONAL ORGANIZATIONS

- 2006-2008 California Medical Association
- 2006-2008 California Association of Eye Physicians and Surgeons
- 2008- American Academy of Ophthalmology, Active Fellow
- 2003- Association for Research in Vision and Ophthalmology
- 2003-2006 Colorado Society of Eye Physicians and Surgeons
- 1998- American Medical Association
- 1998-2006 Colorado Medical Society

LICENSURE & CERTIFICATION

- Colorado # 46779
- DEA #BO9845059

LANGUAGES

- English
- Spanish